AI Life Sciences

AI Life Sciences is a specialized drug discovery and development platform within M42, a global healthcare powerhouse based in Abu Dhabi. Formed as part of M42's strategic restructuring in early 2025, the platform harnesses artificial intelligence, high-throughput genomics, and one of the region's largest biobanks to identify novel therapeutic targets and accelerate the development of next-generation medicines. A cornerstone of its business model is the strategic partnership with longevity biotech leader Juvenescence, through which it is identifying and developing a unique pipeline of AI-enabled therapeutics targeting age-related conditions. Beyond drug discovery, the entity is at the forefront of space health initiatives and precision medicine, aiming to transform Abu Dhabi into a global nexus for AI-driven biomedical innovation. By integrating clinical data from M42's vast network of 480 facilities with advanced computational tools, AI Life Sciences operates as a vertically integrated engine for therapeutic discovery.